Dunedin cancer diagnostics company Pacific Edge has gone back to investors for up to $24 million as it tries to keep its Cxbladder business alive long enough to win back Medicare coverage in the United States.
The dual-listed company, which is on both the NZX main board and the Australian ASX, is selling new shares at 17 cents apiece in a two part offering. An $18 million placement is being made to eligible institutional and wholesale investors, with a further $6 million share purchase plan opening to retail shareholders in New Zealand and Australia. The company has said it is willing to accept oversubscriptions in the retail leg.
The price tag is brutal compared to where the stock has traded historically. According to NBR, the placement alone equates to about 10.1 percent of Pacific Edge’s market capitalisation before the offer, meaning existing shareholders who do not chip in will be diluted significantly. It is also the second large equity raise in 12 months, after the company tapped the market for $20 million last year.
Behind the raise sits a painful set of numbers. RNZ reported that Pacific Edge’s full year net loss has widened to $35.7 million, up from $29.9 million the year before. Revenue almost halved, falling to $11.5 million from $21.8 million, after Medicare administrative contractor Novitas withdrew coverage of the company’s flagship Cxbladder Triage and Cxbladder Detect tests for US patients on Medicare. US testing volumes for the year dropped to 18,784 from 23,885 the year before, and the slide carried into the most recent quarter, with US tests in the three months to December 2025 down to 4,003 from 4,971 in the previous quarter.
The capital raise is essentially a bridge. Pacific Edge has told the market it is targeting monthly cash burn of about $2.5 million for the 2027 financial year while it works through the Medicare process and chases reimbursement deals with private US health insurers. Chair Simon Flood said the company had “firmly established ourselves as the first mover and market leader in bladder cancer diagnostics” and confirmed that all directors would take part in the offer.
Cxbladder is a urine based genetic test developed using intellectual property out of the University of Otago. It looks at RNA biomarkers shed by bladder cancer cells, and is pitched as a less invasive alternative to cystoscopy for patients who turn up with blood in their urine or who are being monitored for recurrence. The product itself has not lost its US Food and Drug Administration backing or its clinical reputation. The fight is over whether American taxpayers, through Medicare, will pay for it, and that fight has now been running for several years.
Two things make the timing of this raise interesting. The first is that Novitas, the Medicare administrative contractor that handles Pacific Edge’s territory, has been edging towards a fresh policy decision. A Contractor Advisory Committee meeting was held in February to gather expert input ahead of a possible new Local Coverage Determination, and Pacific Edge has told the market it expects a draft determination to be released before September 2026. The second is that Pacific Edge has begun stacking up commercial wins in parallel. The Kaiser Permanente real world evidence study showing the clinical utility of Cxbladder Triage has been accepted for publication in the journal Urology Practice, and Avalon Healthcare Systems, which makes coverage decisions for around 44 million American lives, has formally endorsed Cxbladder Triage as meeting its coverage criteria.
None of that translates straight into revenue, but it does suggest a path back to scale if the Medicare door reopens. Pacific Edge’s pitch to investors is that 17 cents a share is the cost of staying in the game until the company finds out whether that door opens, and that the alternative, which would be running out of cash before any decision lands, is worse for shareholders than the dilution.
The raise is also a reminder of how exposed New Zealand listed life sciences companies are to single regulator decisions in much larger markets. Pacific Edge has spent more than a decade trying to convert a piece of Otago university science into commercial revenue in the United States, and one administrative ruling in Texas, where Novitas is based, has been enough to halve its top line. The company employs more than 100 people in Dunedin and is one of the few homegrown medical technology stories the NZX has been able to point to over that period.
For shareholders, the next 12 months will be defined by two questions. Does Novitas issue a draft Local Coverage Determination that puts Cxbladder back on the Medicare schedule, and how quickly can Pacific Edge convert its Avalon and Kaiser style wins into paying contracts with the larger US commercial insurers. The company itself has been clear about the stakes. Chief executive Peter Meintjes told the market earlier in the year that Pacific Edge was entering 2026 in the strongest position it had ever been in to establish enduring Medicare coverage.
Either way, the next milestone is the Novitas draft determination expected before September. The $24 million now being raised is, more than anything, an attempt to make sure the company is still standing when that decision arrives.
Has Pacific Edge’s Medicare fight gone on too long, or is the science worth backing one more time? Drop your thoughts in the comments below.
This article was written by AI, briefed to report the facts, hopefully without some of the bias people bring to the job 🙂
Leave a Reply